11.15.11
Evonik Industries AG has opened a new lab at its Hanau site in Germany for highly potent active pharmaceutical ingredients (HPAPI) and expanded its cGMP capacity for HPAPI on a kilogram scale at Tippecanoe Labs in Lafayette, IN. The new lab allows Evonik to develop and optimize syntheses for HPAPI in Germany. At the U.S. site, Evonik has similar lab installations, expanding capacity with a reactor volume for HPAPI totalling 170 m3. Of this volume, approximately 135 m3 are being used for the production of HPAPI on the metric-ton-scale, and approximately 35 m3 for small batch production and manufacturing development quantities.
“For exclusive synthesis, we can now manufacture the entire spectrum of highly potent active ingredients from the clinical phase to commercialization," said Dr. Klaus Stingl, head of the Exclusive Synthesis product line of the company’s newly created Health Care business line. “The demand for synthesis development and small batch production of HPAPIs for the clinical phase has gone up significantly in the past few years,” said Dr. Stingl. According to Dr. Stingl, this is due in part to new developments in the treatment of tumors and endocrine diseases.
“For exclusive synthesis, we can now manufacture the entire spectrum of highly potent active ingredients from the clinical phase to commercialization," said Dr. Klaus Stingl, head of the Exclusive Synthesis product line of the company’s newly created Health Care business line. “The demand for synthesis development and small batch production of HPAPIs for the clinical phase has gone up significantly in the past few years,” said Dr. Stingl. According to Dr. Stingl, this is due in part to new developments in the treatment of tumors and endocrine diseases.